The selective vitamin d receptor activator for albuminuria lowering (VITAL) study: Study design and baseline characteristics

H. J. Lambers Heerspink, Rajiv Agarwal, D. W. Coyne, H. H. Parving, E. Ritz, G. Remuzzi, P. Audhya, M. J. Amdahl, D. L. Andress, D. De Zeeuw

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Patients with diabetic nephropathy are at high risk for further progressive renal function loss. Treatments that decrease albuminuria have been linked with renal and cardiovascular protection. However, even when taking optimal treatment, residual renal and cardiovascular risk remains high which correlates with the magnitude of residual albuminuria. Use of vitamin D receptor activators, such as calcitriol and paricalcitol, is associated with improved sur- vival. A small study with paricalcitol showed reductions in albuminuria. The VITAL study tests the hypothesis whether paricalcitol persistently reduces albuminuria in diabetic subjects already receiving angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) therapy. Methods: Randomization in this double-blind trial is equal allocation to paricalcitol 1 μ/day, 2 μg/day, or placebo. Inclusion criteria include: a diagnosis of type 2 diabetes, urinary albumin/creatinine ratio (UACR) between 100-3,000 mg/g, estimated glomerular filtration rate (eGFR) between 15-90 ml/min/1.73 m 2, serum calcium <9.8 mg/dl, and parathyroid hormone (PTH) between 35-500 pg/ml. Results: Baseline characteristics of the 281 subjects are: 69% men, mean age 64.9 ± 10.4 years, eGFR 40.7 ± 16.7 ml/min, median UACR (interquartile range) 612.3 mg/g (281-1,181 mg/g) and PTH 98.4 ± 63.8 pg/ml. Conclusion: This trial will be the first clinical test of the hypothesis that paricalcitol possesses pleiotropic effects and can modulate albuminuria in the setting of ACEI and/or ARB therapy. Results will have important clinical implications and are expected in November 2009.

Original languageEnglish
Pages (from-to)280-286
Number of pages7
JournalAmerican Journal of Nephrology
Volume30
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Albuminuria
Vitamins
Angiotensin Receptor Antagonists
Parathyroid Hormone
Glomerular Filtration Rate
Kidney
Angiotensin-Converting Enzyme Inhibitors
Albumins
Creatinine
Calcitriol Receptors
Calcitriol
Diabetic Nephropathies
Therapeutics
Random Allocation
Type 2 Diabetes Mellitus
Placebos
paricalcitol
Calcium
Survival
Serum

Keywords

  • Albuminuria
  • Chronic kidney disease
  • Paricalcitol
  • Vitamin D

ASJC Scopus subject areas

  • Nephrology

Cite this

The selective vitamin d receptor activator for albuminuria lowering (VITAL) study : Study design and baseline characteristics. / Lambers Heerspink, H. J.; Agarwal, Rajiv; Coyne, D. W.; Parving, H. H.; Ritz, E.; Remuzzi, G.; Audhya, P.; Amdahl, M. J.; Andress, D. L.; De Zeeuw, D.

In: American Journal of Nephrology, Vol. 30, No. 3, 09.2009, p. 280-286.

Research output: Contribution to journalArticle

Lambers Heerspink, HJ, Agarwal, R, Coyne, DW, Parving, HH, Ritz, E, Remuzzi, G, Audhya, P, Amdahl, MJ, Andress, DL & De Zeeuw, D 2009, 'The selective vitamin d receptor activator for albuminuria lowering (VITAL) study: Study design and baseline characteristics', American Journal of Nephrology, vol. 30, no. 3, pp. 280-286. https://doi.org/10.1159/000225903
Lambers Heerspink, H. J. ; Agarwal, Rajiv ; Coyne, D. W. ; Parving, H. H. ; Ritz, E. ; Remuzzi, G. ; Audhya, P. ; Amdahl, M. J. ; Andress, D. L. ; De Zeeuw, D. / The selective vitamin d receptor activator for albuminuria lowering (VITAL) study : Study design and baseline characteristics. In: American Journal of Nephrology. 2009 ; Vol. 30, No. 3. pp. 280-286.
@article{8d8ed3dad7c5477995c342b63e508652,
title = "The selective vitamin d receptor activator for albuminuria lowering (VITAL) study: Study design and baseline characteristics",
abstract = "Background: Patients with diabetic nephropathy are at high risk for further progressive renal function loss. Treatments that decrease albuminuria have been linked with renal and cardiovascular protection. However, even when taking optimal treatment, residual renal and cardiovascular risk remains high which correlates with the magnitude of residual albuminuria. Use of vitamin D receptor activators, such as calcitriol and paricalcitol, is associated with improved sur- vival. A small study with paricalcitol showed reductions in albuminuria. The VITAL study tests the hypothesis whether paricalcitol persistently reduces albuminuria in diabetic subjects already receiving angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) therapy. Methods: Randomization in this double-blind trial is equal allocation to paricalcitol 1 μ/day, 2 μg/day, or placebo. Inclusion criteria include: a diagnosis of type 2 diabetes, urinary albumin/creatinine ratio (UACR) between 100-3,000 mg/g, estimated glomerular filtration rate (eGFR) between 15-90 ml/min/1.73 m 2, serum calcium <9.8 mg/dl, and parathyroid hormone (PTH) between 35-500 pg/ml. Results: Baseline characteristics of the 281 subjects are: 69{\%} men, mean age 64.9 ± 10.4 years, eGFR 40.7 ± 16.7 ml/min, median UACR (interquartile range) 612.3 mg/g (281-1,181 mg/g) and PTH 98.4 ± 63.8 pg/ml. Conclusion: This trial will be the first clinical test of the hypothesis that paricalcitol possesses pleiotropic effects and can modulate albuminuria in the setting of ACEI and/or ARB therapy. Results will have important clinical implications and are expected in November 2009.",
keywords = "Albuminuria, Chronic kidney disease, Paricalcitol, Vitamin D",
author = "{Lambers Heerspink}, {H. J.} and Rajiv Agarwal and Coyne, {D. W.} and Parving, {H. H.} and E. Ritz and G. Remuzzi and P. Audhya and Amdahl, {M. J.} and Andress, {D. L.} and {De Zeeuw}, D.",
year = "2009",
month = "9",
doi = "10.1159/000225903",
language = "English",
volume = "30",
pages = "280--286",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - The selective vitamin d receptor activator for albuminuria lowering (VITAL) study

T2 - Study design and baseline characteristics

AU - Lambers Heerspink, H. J.

AU - Agarwal, Rajiv

AU - Coyne, D. W.

AU - Parving, H. H.

AU - Ritz, E.

AU - Remuzzi, G.

AU - Audhya, P.

AU - Amdahl, M. J.

AU - Andress, D. L.

AU - De Zeeuw, D.

PY - 2009/9

Y1 - 2009/9

N2 - Background: Patients with diabetic nephropathy are at high risk for further progressive renal function loss. Treatments that decrease albuminuria have been linked with renal and cardiovascular protection. However, even when taking optimal treatment, residual renal and cardiovascular risk remains high which correlates with the magnitude of residual albuminuria. Use of vitamin D receptor activators, such as calcitriol and paricalcitol, is associated with improved sur- vival. A small study with paricalcitol showed reductions in albuminuria. The VITAL study tests the hypothesis whether paricalcitol persistently reduces albuminuria in diabetic subjects already receiving angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) therapy. Methods: Randomization in this double-blind trial is equal allocation to paricalcitol 1 μ/day, 2 μg/day, or placebo. Inclusion criteria include: a diagnosis of type 2 diabetes, urinary albumin/creatinine ratio (UACR) between 100-3,000 mg/g, estimated glomerular filtration rate (eGFR) between 15-90 ml/min/1.73 m 2, serum calcium <9.8 mg/dl, and parathyroid hormone (PTH) between 35-500 pg/ml. Results: Baseline characteristics of the 281 subjects are: 69% men, mean age 64.9 ± 10.4 years, eGFR 40.7 ± 16.7 ml/min, median UACR (interquartile range) 612.3 mg/g (281-1,181 mg/g) and PTH 98.4 ± 63.8 pg/ml. Conclusion: This trial will be the first clinical test of the hypothesis that paricalcitol possesses pleiotropic effects and can modulate albuminuria in the setting of ACEI and/or ARB therapy. Results will have important clinical implications and are expected in November 2009.

AB - Background: Patients with diabetic nephropathy are at high risk for further progressive renal function loss. Treatments that decrease albuminuria have been linked with renal and cardiovascular protection. However, even when taking optimal treatment, residual renal and cardiovascular risk remains high which correlates with the magnitude of residual albuminuria. Use of vitamin D receptor activators, such as calcitriol and paricalcitol, is associated with improved sur- vival. A small study with paricalcitol showed reductions in albuminuria. The VITAL study tests the hypothesis whether paricalcitol persistently reduces albuminuria in diabetic subjects already receiving angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) therapy. Methods: Randomization in this double-blind trial is equal allocation to paricalcitol 1 μ/day, 2 μg/day, or placebo. Inclusion criteria include: a diagnosis of type 2 diabetes, urinary albumin/creatinine ratio (UACR) between 100-3,000 mg/g, estimated glomerular filtration rate (eGFR) between 15-90 ml/min/1.73 m 2, serum calcium <9.8 mg/dl, and parathyroid hormone (PTH) between 35-500 pg/ml. Results: Baseline characteristics of the 281 subjects are: 69% men, mean age 64.9 ± 10.4 years, eGFR 40.7 ± 16.7 ml/min, median UACR (interquartile range) 612.3 mg/g (281-1,181 mg/g) and PTH 98.4 ± 63.8 pg/ml. Conclusion: This trial will be the first clinical test of the hypothesis that paricalcitol possesses pleiotropic effects and can modulate albuminuria in the setting of ACEI and/or ARB therapy. Results will have important clinical implications and are expected in November 2009.

KW - Albuminuria

KW - Chronic kidney disease

KW - Paricalcitol

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=66749092987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749092987&partnerID=8YFLogxK

U2 - 10.1159/000225903

DO - 10.1159/000225903

M3 - Article

C2 - 19521070

AN - SCOPUS:66749092987

VL - 30

SP - 280

EP - 286

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 3

ER -